Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of ADI-212

Next Previous
Trial Profile

A study of ADI-212

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI 212 (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Jan 2026 According to Adicet Bio media relase, the company expects to initiate clinical startup activities for this trial in 2H 2026, subject to regulatory clearance to proceed with it.
  • 01 Dec 2025 New trial record
  • 05 Nov 2025 According to Adicet Bio media relase, company expect to submit a regulatory filing for the mCRPC program in the first quarter of 2026 and share initial clinical data in the second half of 2026, subject to regulatory clearance

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top